Navigation Links
Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
Date:3/15/2012

PITTSBURGH and TORONTO, March 15, 2012 /PRNewswire/ -- Mylan Pharmaceuticals ULC, the Canadian subsidiary of Mylan Inc. (NASDAQ: MYL), today received approval from Health Canada for Mylan-Rosuvastatin Calcium Tablets, 5mg, 10mg, 20mg and 40mg. Mylan-Rosuvastatin is the generic version of Astra Zeneca's Crestor® Tablets, which are used for the management of primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia.  According to IMS Health, Rosuvastatin Calcium Tablets, 5mg, 10mg, 20mg and 40mg, had Canadian sales of approximately $742 million for the 12 months ending Dec. 31, 2011.

"We are very pleased to introduce Mylan-Rosuvastatin to the Canadian market," said Dick Guest, president of Mylan Canada. "According to the Canadian Heart and Stroke Foundation, 'about 40% of Canadians have high blood cholesterol.'[1] Not only does this introduction provide Canadians with access to our quality medicine, it does so at a substantially lower cost. The introduction of generic medicines like Mylan-Rosuvastatin helps to contribute to a sustainable health care system."

Currently, Mylan Canada has 42 product applications pending Health Canada approval representing $3.6 billion in annual sales, according to IMS Health.

In Canada, generic drugs cost consumers an average of 60% less than their brand name counterparts. 

Mylan-Rosuvastatin is contraindicated in patients who are hypersensitive to it and in patients with active liver disease.  Pregnant women or women wishing to become pregnant should not take Rosuvastatin, as well as patients taking cyclosporine.

About Mylan
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan in Canada, please visit www.mylan.ca. For more information about generic drugs, please visit www.ChoosingGenerics.ca.

[1] http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm  


'/>"/>
SOURCE Mylan Pharmaceuticals ULC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):